This article is more than 5 years old. Information may no longer be current.

ContraVir expands advisory board with HBV experts

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Jordan Feld, MD, MPH, a member of the HCV Next Editorial Board, is among a number of hepatitis B virus experts who have been added to the scientific advisory board at ContraVir Pharmaceuticals, according to a press release.

Feld is an internationally recognized clinical and laboratory researcher in viral hepatitis at University Health Network, Toronto General Hospital Liver Center, and McLaughlin-Rotman Centre for Global Health in Toronto. He joins Carol L. Brosgart, MD, who was named chairwoman of the advisory board at ContraVir, and four other HBV experts.

Jordan Feld

“Curing hepatitis B is at the forefront of ContraVir’s research and business strategy,” John-Sullivan Bolyai, MD, MPH, chief medical officer for the company, said in the release. “Aligning the [scientific advisory board] with that goal is another important step toward achieving this vision. The mechanisms of action of our two novel HBV drugs, CMX157 and CRV431, are distinct and complementary to each other. As next-generation derivatives of proven antiviral compounds, each has demonstrated potentially best-in-class potency in vitro.”

Brosgart is a clinical professor of medicine, biostatistics and epidemiology at the University of California, San Francisco. She also has held senior management positions in biotechnology with Gilead Sciences and Alios BioPharma.

Also appointed to the board were: Phillippe Gallay, PhD, a professor at The Scripps Research Institute in La Jolla, California; Nathaniel Katz, MD, an adviser for ContraVir on a phase 3 study of FV-100 for shingles and post-herpetic neuralgia; Jörg Petersen, MD, PhD, a professor and head of the liver unit for viral hepatitis at the IFI Institute at the University of Hamburg; and Fabien Zoulim, MD, PhD, head of the hepatology department at Hospices Civils de Lyon and head of the viral hepatitis team at the Cancer Research Center of Lyon.

Disclosure: Infectious Disease News was unable to confirm relevant financial disclosures at the time of publication.